Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence
March 2, 2015
- Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka
March 2, 2015
- Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
- MTPC Eyes Total Sales of Over 100 Billion Yen for Remicade, Simponi
February 27, 2015
- Takeda Launches Takecab, to Copromote with Otsuka
February 27, 2015
- Medicago Signs Up with US Govt Agency for Development of Production Process for Ebola Antibodies
February 27, 2015
- Shionogi to Reorganize in April to Beat Biz Strategy Goals for FY2020
February 26, 2015
- Avigan Shows Promise in Treatment of Ebola in Clinical Trial
February 26, 2015
- NanoCarrier Concludes Joint Research Agreement with Chugai to Develop Next-Generation Anticancer Drugs
February 26, 2015
- Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS
February 26, 2015
- Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
- Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
- Japan’s 6th SGLT-2 Inhibitor Jardiance Hits Market
February 25, 2015
- US FDA Accepts NDA for Lonsurf: Taiho
February 24, 2015
- Takeda, Queen Mary University of London to Collaborate for Novel Drug Discovery in Gastroenterology Field
February 24, 2015
- MHLW OKs Additional Indications for E Keppra, Adempas
February 23, 2015
- Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
- Pfizer Japan Receives Approval for Japan’s 1st Propecia Generic
February 23, 2015
- Bristol-Myers Files Eliquis for Venous Thromboembolism
February 20, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…